Dermalax Implant: A Guide to Regulatory Status for Professional Sourcing

Dermalax Implant is a hyaluronic acid (HA) dermal filler manufactured by Hugel, a prominent South Korean biopharmaceutical company. As a product from South Korea, its primary domestic approval typically stems from the Korean Ministry of Food and Drug Safety (KFDA). Understanding the origin and manufacturer is the first step in verifying its international market standing and quality benchmarks, often established through adherence to Good Manufacturing Practices (GMP).

As a South Korean-originated product, Dermalax Implant is expected to hold KFDA approval for distribution and use within its home country. This approval signifies that the product meets specific safety, quality, and efficacy standards set by the Korean regulatory body. Hugel's manufacturing facilities are also expected to operate under strict GMP guidelines, a prerequisite for producing injectable medical devices. GMP compliance ensures consistent production and quality control, which is essential for any product within the Hyaluronic acid dermal filler catalog.

For distribution within the European Union (EU) and other markets that recognize the CE Mark (e.g., UK after Brexit, with specific local adaptations), products like Dermalax Implant typically require a valid CE Mark. This certification indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA). Clinic owners in these regions should verify the current CE Mark status for Dermalax Implant before sourcing. [VERIFY: Current CE Mark status for Dermalax Implant.] Other products, such as UNIONFILL, also demonstrate varying levels of market penetration based on such certifications.

Gaining approval from the U.S. Food and Drug Administration (FDA) involves a rigorous process for dermal fillers, typically requiring extensive clinical data. The FDA status dictates whether a product can be legally imported and marketed in the United States. Professionals intending to source Dermalax Implant for the US market must confirm its specific FDA clearance or approval status. [VERIFY: Current FDA status for Dermalax Implant for use in the United States.] Similarly, other HA fillers like Elasty Plus 1CC have distinct regulatory pathways in different jurisdictions.

Beyond the major regulatory bodies, Dermalax Implant’s availability in markets such as the GCC (Gulf Cooperation Council), LATAM (Latin America), and other APAC (Asia-Pacific) countries is determined by local health authority registrations. These registrations often involve recognizing existing approvals like KFDA or CE, alongside specific national requirements for product labeling, import permits, and distributor licensing. Sourcing professionals should verify local regulatory approval in their specific operational regions to ensure compliance. For example, similar considerations apply when sourcing products detailed in the Chaeum Premium No. 3: Professional Sourcing Guide.

When sourcing Dermalax Implant, clinics and resellers must prioritize suppliers who can provide full transparency regarding regulatory compliance. This includes documentation such as certificates of origin, KFDA approval, and any applicable CE Mark certificates. Professionals should also inquire about cold chain maintenance during shipping and demand traceability for lot numbers. The illustrative wholesale price for Dermalax Implant is approximately $95.4/unit, with volume tiers offering discounts: 11 units (4%), 21 units (5%), 31 units (6%), and 51+ units (8%). However, pricing should always be secondary to verifying regulatory compliance and product authenticity.